Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-Amino-3-(Cystein-S-Yl)-Isoxazolidin-5-Yl-Acetic Acid is a synthetic small molecule belonging to the class of L-cysteine-S-conjugates. It has the chemical formula C8H15N3O5S and a molecular weight of approximately 265.29 g/mol[4][1][5]. The compound is experimental and not approved for clinical use in any country[4]. There are no known approved indications or marketed formulations. Its structure features an isoxazolidine ring conjugated via sulfur to an L-cysteine residue. No detailed mechanism of action or pharmacological activity has been established in humans; however, related compounds have been studied as potential modulators of glutamate receptors such as AMPA and kainate receptors in preclinical research[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-amino-3-(cystein-s-yl)-isoxazolidin-5-yl-acetic acid.